Clinically actionable genomic alterations in breast cancer brain metastases.
Brain tumors from breast cancer have more actionable genetic changes than primary tumors, arguing for rebiopsy to guide precision therapy at progression.
This study characterizes the genomic landscape of breast cancer brain metastases, identifying actionable alterations at significantly higher rates than primary tumors, which has direct implications for trial enrollment and targeted therapy selection at CNS progression. The findings provide the rationale for mandatory tissue re-biopsy at brain metastasis to guide precision therapy.
What the study was
- Study design
- Molecular profiling study (cohort of breast cancer brain metastases)
- Population
- Breast cancer patients with brain metastases
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- ESMO open
Why it surfaced
Actionable genomic profiling data in BCBM, one of the highest-unmet-need settings in breast cancer; directly supports treatment strategy change at CNS progression.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.